Engineered Bacteria Could Become Precision Weapons Against Tumors
A new perspective in Nature Cancer outlines how genetically engineered bacteria can target and destroy tumors from within.
675 articles in this topic
A new perspective in Nature Cancer outlines how genetically engineered bacteria can target and destroy tumors from within.
A completed French trial explores how gut and airway microbiota, blood, and sputum biomarkers relate to immunotherapy outcomes in metastatic NSCLC.
A phase 2 trial tests obinutuzumab, ibrutinib, and venetoclax in Richter's syndrome, a deadly CLL transformation with few treatment options.
A large genomic study finds mesenchymal glioblastoma responds better to immune checkpoint blockade, opening a path to smarter patient selection.
A macrophage-derived metabolite rewires tumor metabolism and flips immune cells from tumor-promoting to tumor-fighting.
Disabling the NFIL3 protein prevents CAR T cell exhaustion, boosting tumor-fighting power in animal models of hard-to-treat cancers.
Inhibiting the mitophagy kinase PINK1 amplifies mitochondrial ROS, activating a BAX-caspase-GSDME cascade that destroys neuroblastoma cells via pyroptosis.
END-seq reveals ALT-positive cancer telomeres share canonical 5′ ATC termini with normal cells, but harbor uniquely abundant single-stranded DNA regions.
A landmark WGS study of 1,804 myeloid neoplasia patients uncovers how telomere length varies by mutation type and cancer subtype.
Intratumoral senescent cells shielded by PD-L2 may explain why chemotherapy often falls short — and point to a new combination strategy.
Fusobacterium nucleatum has shifted from suspected bystander to confirmed cancer driver — here's what the science reveals.
New review reveals how cancer biology has fundamentally transformed our understanding of mitochondrial plasticity and its implications beyond oncology.